Analysis of Tuberculosis Cases with a Different Range of Mutations in Pathogen Genes Associated with Resistance to Isoniazid and Rifampicin
https://doi.org/10.58838/2075-1230-2025-103-1-74-78
Abstract
The objective: to analyze cases of tuberculosis with a different range of mutations in the M. tuberculosis genes associated with resistance to isoniazid and rifampicin, to determine prevalence of such mutations, clinical significance and molecular genetic characteristics of pathogens. The cases detected in Saratov Oblast were included in the analysis.
Subjects and Methods. A total of 437 sputum samples obtained from HIV-negative tuberculosis patients in 2006-2020 living in
Saratov Oblast were examined by biological microarray method. The range of mutations was studied in katG, inhA, ahpC genes associated with drug resistance to isoniazid and in rpoB gene associated with drug resistance to rifampicin.
Results. DNA of M. tuberculosis was isolated from 70.9% of samples, of which 53.8% had mutations. Single-nucleotide substitutions in one of katG, inhA, ahpC, rpoB genes were found in 36.1%, double mutations were found in 10.9%, and multiple mutations (substitutions of three or more nucleotides) were found in 6.8%. The largest number of double and multiple mutations was registered in rpoB gene - 8.9% and 10.2%, respectively. The largest number of combined mutations in different genes was observed in the combination katG+rpoB – 23.4% and katG+inhA+rpoB – 19.2% 17 (5.48%) samples with simultaneous multiple and combined mutations in different genes katG, inhA, ahpC were identified. Of these, 14 (82.3%) people had multiple mutations in katG, inhA, ahpC genes combined with multiple mutations in rpoB gene, of which 57.2% had severe forms of tuberculosis with destruction and positive results of sputum tests. Thus in Saratov Oblast among patients with pulmonary tuberculosis, a group was identified in which M. tuberculosis had multiple mutations in katG, inhA, ahpC genes in combination with multiple mutations in rpoB gene.
About the Authors
T. Yu. Salina
V.I. Razumovsky Saratov State Medical University, Russian Ministry of Health
Russian Federation
Tatiana Yu. Salina - Doctor of Medical Sciences, Professor of Phthisiology Department, Institute of Higher Professional Training and Further Professional Education
Russian Federation
Tatiana Yu. Salina - Doctor of Medical Sciences, Professor of Phthisiology Department, Institute of Higher Professional Training and Further Professional Education
112 Bolshaya Kazachya St., Saratov, 410012 Phone: + 7 (845) 226-56-08
T. I. Morozova
V.I. Razumovsky Saratov State Medical University, Russian Ministry of Health
Russian Federation
Tatyana I. Morozova - Doctor of Medical Sciences, Professor, Head of Phthisiology Department, Institute of Higher Professional Training and Further Professional Education
Russian Federation
Tatyana I. Morozova - Doctor of Medical Sciences, Professor, Head of Phthisiology Department, Institute of Higher Professional Training and Further Professional Education
112 Bolshaya Kazachya St., Saratov, 410012 Phone: + 7 (845) 226-56-08
References
1. Burmistrova I.A., Samoylova A.G., Tyulkova T.E., Vaniev E.V., Balasayants G.S., Vasilyeva I.A. Drug resistance of M. tuberculosis (historical aspects, current level of knowledge). Tuberculosis and Lung Diseases, 2020, vol. 98, no. 1, pp. 54-60. (In Russ.)
2. Liu L. Jiang F., Chen L., Zhao B., Dong J., Sun L., Zhu Y., Liu B., Zhou Y., Yang J., Zhao Y., Jin Qi., Zhang X. The impact of combined gene mutations in inhA and ahpC genes on high levels of isoniazid resistance amongst katG non-315 in multidrug-resistant tuberculosis isolates from China // Emerging Microbes & Infections. – 2018. – Vol. 7, № 1. – P. 1-10.
3. Mitchinson D.A. How drug resistance emerges as a result of poor compliance during short course chemotherapy of tuberculosis // Inf. J. Tuberc. Lung Dis. – 1998. – № 2. – P. 10-15.
4. Qadir M., Tahseen S., McHugh T.D., Hussain A., Masood F., Ahmed N., Faryal Profiling and identification of novel rpoB mutations in rifampicin-resistant Mycobacterium tuberculosis clinical isolates from Pakistan // J. Infect Chemother. – 2021. – Vol. 27, № 11. – P. 1578-1583.
5. WHO consolidated guidelines on tuberculosis. Module 4: Treatment – drug-resistant tuberculosis treatment, 2022 update. Geneva: World Health Organization; 2022. Available at: https://iris.who.int/handle/10665/365308 [Accessed Okt 01, 2024].
6. Wilson T.M., de Lisle G.W., Collins D.M. Effect of inhA and katG on isoniazid resistance and virulence of Mycobacterium bovis // Molecular Microbiology. – 1995. – Vol. 156, № 6. – P. 1009-1015.
7. Woodmann M., Hatusler I.L., Grandjean L. Tuberculosis Genetic Epidemiology: A Latin American Perspective // Genes. – 2019. – Vol. 10, № 1. – Р. 53. https://doi.org/10.3390/genes10010053
8. Zhang Q., An X., Liu H., Wang S., Xiao T., Liu H. Uncovering the resistance mechanism of Mycobacterium tuberculosis to Rifampicin Due to RNA Polymerase H451D/Y/R Mutations From Computational Perspective // Front Chem. – 2019. – № 7. – Р. 819.
Review
For citations:
Salina T.Yu., Morozova T.I. Analysis of Tuberculosis Cases with a Different Range of Mutations in Pathogen Genes Associated with Resistance to Isoniazid and Rifampicin. Tuberculosis and Lung Diseases. 2025;103(1):74-78. (In Russ.) https://doi.org/10.58838/2075-1230-2025-103-1-74-78
Views:
195
Email this article 